Apoptosis, p53, and tumor cell sensitivity to anticancer agents

Cancer Research

Volumn 59, Issue 7, 1999, Pages 1391-1399

  Brown, J Martin ^a   Wouters, Bradly G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; CELL DEATH; CELL KILLING; CELL SURVIVAL; CELL TRANSFORMATION; DNA DAMAGE; GENE MUTATION; MALIGNANT TRANSFORMATION; MOUSE; MULTIGENE FAMILY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA; DNA DAMAGE; GENES, BCL-2; GENES, P53; HUMANS;

EID: 0033118475     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. McGill, G., and Fisher, D. E. Apoptosis in tumorigenesis and cancer therapy. Frontiers Biosci., 2: 353-379, 1997.
2. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem., 60: 23-32, 1996.
3. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
4. Komarova, E. A., Chernov, M. V., Franks, R., Wang, K., Armin, G., Zelnick, C. R., Chin, D. M., Bacus, S. S., Stark, G. R., and Gudkov, A. V. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J., 16: 1391-1400, 1997.
5. Rudin, C. M., and Thompson, C. B. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu. Rev. Med., 48: 267-281, 1997.
6. Elledge, R. M. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? J. Natl. Cancer Inst., 88: 141-143, 1996.
7. Falette, N., Paperin, M. P., Treilleux, I., Gratadour, A. C., Peloux, N., Mignotte, H., Tooke, N., Lofman, E., Inganas, M., Bremond, A., Ozturk, M., and Puisieux, A. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res., 58: 1451-1455, 1998.
8. Pai, H. H., Rochon, L., Clark, B., Black, M., and Shenouda, G. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 41: 37-42, 1998.
9. Wiggenraad, R., Tamminga, R., Blok, P., Rouse, R., and Hermans, J. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 41: 29-35, 1998.
10. Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., and Skinner, D. G. p53 and treatment of bladder cancer. Nature (Lond.), 385: 123-125, 1997.
11. Tada, M., Matsumoto, R., Iggo, R. D., Onimaru, R., Shirato, H., Sawamura, Y., and Shinohe, Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res., 58: 1793-1797, 1998.
12. Bosari, S., and Viale, G. The clinical significance of p53 aberrations in human tumours. Virchows Arch., 427: 229-241, 1995.
13. Weinberg, R. A. How cancer arises. Sci. Am., 275: 62-70, 1996.
14. El-Deiry, W. S. The p53 pathway and cancer therapy. Cancer J., 11: 229-236, 1998.
15. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC)., 266: 807-810, 1994.
16. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
17. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Jr., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johnson, G. S., Wittes, R. E., and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC), 275: 343-349, 1997.
18. Aldridge, D. R., Arends, M. J., and Radford, I. R. Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response. Br. J. Cancer, 71: 571-577, 1995.
19. Han, J. W., Dionne, C. A., Kedersha, N. L., and Goldmacher, V. S. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc. Cancer Res., 57: 176-182, 1997.
20. Lock, R. B., and Stribinskiene, L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res., 56: 4006-4012, 1996.
21. Kyprianou, N., King, E. D., Bradbury, D., and Rhee, J. G. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer, 70: 341-348, 1997.
22. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
23. Wouters, B. G., Giaccia, A. J., Denko, N. C., and Brown, J. M. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res., 57: 4703-4706, 1997.
24. Thompson, L. H., and Suit, H. D. Proliferation kinetics of x-irradiated mouse L cells studied with time-lapse photography II. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 15: 347-362, 1969.
25. 125IUdR-release assay for measuring the kinetics of cell death. Int. J. Radiat. Biol., 59: 397-408, 1991.
26. Vidair, C. A., Chen, C. H., Ling, C. C., and Dewey, W. C. Apoptosis induced by X-irradiation of rec-myc cells is postmitotic and not predicted by the lime after irradiation or behavior of sister cells. Cancer Res., 56: 4116-4118, 1996.
27. Puck, T. T., and Markus, P. I. Action of X-rays on mammalian cells. J. Exp. Med., 103: 653-666, 1956.
28. Durand, R. E. Cure, regression and cell survival: a comparison of common radiobiological endpoints using an in vitro tumour model. Br. J. Radiol., 48: 556-571, 1975.
29. Reinhold, H. S., and De Bree, C. Tumour cure rate and cell survival of a transplantable rat rhabdomyosarcoma following X-irradiation. Eur. J. Cancer, 4: 367-374, 1968.
30. Skipper, H. E., Schabel, F. M., and Wilcox, W. S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemias. Cancer Chemother. Rep., 35: 1-111, 1964.
31. Begg, A. C. Principles and practice of the tumor growth delay assay. In: R. F. Kallman (ed.), Rodent tumor models in experimental cancer therapy, pp. 114-121. Oxford, England: Pergamon Press, 1987.
32. Wong, C. S., and Hill, R. P. Experimental radiotherapy. In: I. F. Tannock and R. F. Hill (eds.), The Basic Science of Oncology, Ed. 3, pp. 322-349. New York: McGraw-Hill, 1998.
33. Lamb, J. R., and Friend, S. H. Which guesstimale is the best guesstimate? Predicting chemotherapeutic oulcomes. Nat. Med., 3: 962-963, 1997.
34. Gura, T. Cancer models: systems for idenlifying new drugs are often faulty. Science (Washington DC), 278: 1041-1042, 1997.
35. Boyer, M. J., and Tannock, I. F. Cellular and molecular basis of chemotherapy. In: I. F. Tannock and R. F. Hill (eds.), The Basic Science of Oncology, Ed. 3, pp. 350-369. New York: McGraw-Hill, 1998.
36. Yin, D. X., and Schimke, R. T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res., 55: 4922-4928, 1995.
37. Dewey, W. C., Ling, C. C., and Meyn, R. E. Radiation-induced apoptosis: relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 33: 781-796, 1995.
38. Zamble, D. B., Jacks, T., and Lippard, S. J. p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl. Acad. Sci. USA, 95: 6163-6168, 1998.
39. Polten, C. S. What is an apoptotic index measuring? A commentary. Br. J. Cancer, 74: 1743-1748, 1996.
40. Gallardo, D., Drazan, K. E., and McBride, W. H. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res., 56: 4891-4893, 1996.
41. Gjerset, R. A., and Sobel, R. E. Treatment resistance, apoplosis, and p53 tumor suppressor gene therapy. In: J. R. Bertino (ed.), Encyclopedia of Cancer, pp. 1785-1791. San Diego: Academic Press, 1997.
42. Peacock, J., Chung, S., Benchimol, S., and Hill, R. P. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene, 9: 1527-1536, 1994.
43. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
44. Siles, E., Villalobos, M., Valenzuela, M. T., Nunez, M. I., Gordon, A., McMillan, T. J., Pedraza, V., and Ruiz de Almodovar, J. M. Relationship between p53 status and radiosensitivity in human tumour cell lines. Br. J. Cancer, 73: 581-588, 1996.
45. Zaffaroni, N., Benini, E., Gornati, D., Bearzatto, A., and Silvestrini, R. Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells, 13: 77-85, 1995.
46. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667-3669, 1993.
47. Jung, M., Notario, V., and Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res., 52: 6390-6393, 1992.
48. Ribeiro, J. C., Bametson, A. R., Fisher, R. J., Mameghan, H., and Russell, P. J. Relationship between radiation response and p53 status in human bladder cancer cells. Int. J. Radiat. Biol., 72: 11-20, 1997.
49. Zolzer, F., Hillebrandt, S., and Streffer, C. Radiation induced G1-block and p53 status in six human cell lines. Radiother. Oncol., 37: 20-28, 1995.
50. Biard, D. S., Martin, M., Rhun, Y. L., Duthu, A., Lefaix, J. L., May, E., and May, P. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res., 54: 3361-3364, 1994.
51. Servomaa, K., Kiuru, A., Grenman, R., Pekkola-Heino, K., Pulkkinen, J. O., and Rytomaa, T. p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif., 29: 219-230, 1996.
52. Pardo, F. S., Su, M., Borek, C., Preffer, F., Dombkowski, D., Gerweck, L., and Schmidt, E. V. Transfection of rat embryo cells with mutant p53 increases the intrinsic radiation resistance. Radiat. Res., 140: 180-185, 1994.
53. Gupta, N., Vij, R., Haas-Kogan, D. A., Israel, M. A., Deen, D. F., and Morgan, W. F. Cytogenetic damage and the radiation-induced G1-phase checkpoint. Radiat Res., 145: 289-298, 1996.
54. Bristow, R. G., Jang, A., Peacock, J., Chung, S., Benchimol, S., and Hill, R. P. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene, 9: 1527-1536, 1994.
55. Yount, G. L., Haas-Kogan, D. A., Vidair, C. A., Haas, M., Dewey, W. C., and Israel, M. A. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res., 56: 500-506, 1996.
56. Tsang, N. M., Nagasawa, H., Li, C., and Little, J. B. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene, 10: 2403-2408, 1995.
57. DeWeese, T. L., Walsh, J. C., Dillehay, L. E., Kessis, T. D., Hedrick, L., Cho, K. R., and Nelson, W. G. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. Int. J. Radiat. Oncol. Biol. Phys., 37: 145-154, 1997.
58. Hendry, J. H., Adecko, A., Potten, C. S., and Morris, I. D. p53 deficiency produces fewer regenerating spermatogenic tubules after irradiation. Int. J. Radiat. Biol., 70: 677-682, 1996.
59. Hendry, J. H., Cai, W. B., Roberts, S. A., and Potten, C. S. p53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiat. Res., 148: 254-259, 1997.
60. Huang, H., Li, C. Y., and Little, J. B. Abrogation of p53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumour cells to ionizing radiation. Int. J. Radiat. Biol., 70: 151-160, 1996.
61. Slichenmyer, W. J., Nelson, W. G., Slebos, R. J., and Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
62. Westphal, C. H., Rowan, S., Schmaltz, C., Elson, A., Fisher, D. E., and Leder, P. atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nat. Genet., 16: 397-401, 1997.
63. Zellars, R. C., Naida, J. D., Davis, M. A., and Lawrence, T. S. Effect of p53 overexpression on radiation sensitivity of human colon cancer cells. Radiat. Oncol. Investig., 5: 43-49, 1997.
64. Merritt, A. J., Allen, T. D., Potten, C. S., and Hickman, J. A. Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene, 14: 2759-2766, 1997.
65. Kawashima, K., Mihara, K., Usuki, H., Shimizu, N., and Namba, M. Transfecled mutant p53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. Int. J. Cancer, 61: 76-79, 1995.
66. Pellegata, N. S., Antoniono, R. J., Redpath, J. L., and Stanbridge, E. J. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc. Natl. Acad. Sci. USA. 93: 15209-15214, 1996.
67. Bristow, R. G., Hu, Q., Jang, A., Chung, S., Peacock, J., Benchimol, S., and Hill, R. Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. Oncogene, 16: 1789-1802, 1998.
68. Fan, S., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., Jr., and O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997.
69. Aldridge, D. R., and Radford, I. R. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res., 58: 2817-2824, 1998.
70. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
71. Brown, J. M. NCI's anticancer drug screening program may not be selecting for clinically active compounds. Oncol. Res., 9: 213-215, 1997.
72. Rupnow, B. A., Murtha, A. D., Alarcon, R. M., Giaccia, A. J., and Knox, S. J. Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res., 58: 1779-1784, 1998.
73. Ling, C. C., Guo, M., Chen, C. H., and Deloherey, T. Radiation-induced apoptosis: effects of cell age and dose fractionation. Cancer Res., 55: 5207-5212, 1995.
74. Lowe, S. W., Jacks, T., Housman, D. E., and Ruley, H. E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficicnt cells. Proc. Natl. Acad. Sci. USA, 91: 2026-2030, 1994.
75. Sanchez-Prieto, R., Quintanilla, M., Cano, A., Leonart, M. L., Martin, P., Anaya, A., and Ramon y Cajal, S. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene, 13: 1083-1092, 1996.
76. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
77. Pan, H., and Griep, A. E. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev., 8: 1285-1299, 1994.
78. Guo, M., Chen, C., Vidair, C., Marino, S., Dewey, W. C., and Ling, C. C. Characterization of radiation-induced apoptosis in rodent cell lines. Radiat. Res., 147: 295-303, 1997.
79. Hermeking, H., and Eick, D. Mediation of c-myc-induced apoptosis by p53. Nature (Lond.), 265: 2091-2093, 1994.
80. Bissonnette, R. P., Echeverri, F., Mahboubi, A., and Green, D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (Lond.), 359: 552-554, 1992.
81. Fanidi, A., Harrington, E. A., and Evan, G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (Lond.), 359: 554-556, 1992.
82. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
83. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
84. de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S. Y., Ferbeyre, G., Samuelson, A. V., Prives, C., Roussel, M. F., Sherr, C. J., and Lowe, S. W. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev., 12: 2434-2442, 1998.
85. Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev., 12: 2424-2433, 1998.
86. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA, 95: 8292-8297, 1998.
87. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell, 91: 649-659, 1997.
88. McGill, G., Shimamura, A., Bates, R. C., Savage, R. E., and Fisher, D. E. Loss of matrix adhesion triggers rapid transformation-selective apoptosis in fibroblasts. J. Cell Biol., 138: 901-911, 1997.
89. Nikiforov, M. A., Hagen, K., Ossovskaya, V. S., Connor, T. M., Lowe, S. W., Deichman, G. I., and Gudkov, A. V. p53 modulation of anchorage independent growth and experimental metastasis. Oncogene. 13: 1709-1719, 1996.
90. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond.), 381: 713-716, 1996.